Prognostic factors of perioperative FLOT regimen in operable gastric and gastroesophageal junction tumors: real-life data (Turkish Oncology Group)

Basit Öğe Kaydı
dc.contributor.authorErol, Cihan
dc.contributor.authorSakin, Abdullah
dc.contributor.authorBasoglu, Tugba
dc.contributor.authorOzden, Ercan
dc.contributor.authorCabuk, Devrim
dc.contributor.authorDogan, Mutlu
dc.contributor.authorOksuzoglu, Berna
dc.date.accessioned2024-02-23T14:41:44Z
dc.date.available2024-02-23T14:41:44Z
dc.date.issued2022
dc.departmentNEÜen_US
dc.description.abstractBackground/aim: Perioperative FLOT regimen is a standard of care in locally advanced operable gastric and GEJ adenocarcinoma. We aimed to determine the efficacy, prognostic factors of perioperative FLOT chemotherapy in real-life gastric and GEJ tumors. Materials and methods: The data of patients who were treated with perioperative FLOT chemotherapy were retrospectively analyzed from 34 different oncology centers in Turkey. Baseline clinical and demographic characteristics, pretreatment laboratory values, histological and molecular characteristics were recorded. Results: A total of 441 patients were included in the study. The median of age our study population was 60 years. The majority of patients with radiological staging were cT3-4N(+) (89.9%, n = 338). After median 13.5 months (IQR: 8.5-20.5) follow-up, the median overall survival was NR (95% CI, NR to NR), and median disease free survival was 22.9 (95% CI, 18.6 to 27.3) months. The estimated overall survival at 24 months was 62%. Complete pathological response (pCR) and near pCR was achieved in 23.8% of all patients. Patients with lower NLR or PLR have significantly longer median OS (p = 0.007 and p = 0.033, respectively), and patients with lower NLR have significantly longer median DFS (p = 0.039), but PLR level did not affect DFS (p = 0.062). The OS and DFS of patients with better ECOG performance scores and those who could receive FLOT as adjuvant chemotherapy instead of other regimens were found to be better. NLR was found to be independent prognostic factor for OS in the multivariant analysis. At least one adverse event reported in 57.6% of the patients and grade 3-4 toxicity was seen in 23.6% patients. Conclusion: Real-life perioperative FLOT regimen in operable gastric and GEJ tumors showed similar oncologic outcomes compared to clinical trials. Better performance status, receiving adjuvant chemotherapy as same regimen, low grade and low NLR and PLR improved outcomes in real-life. However, in multivariate analysis, only NLR affected OS.en_US
dc.identifier.doi10.55730/1300-0144.5404
dc.identifier.endpage1032en_US
dc.identifier.issn1300-0144
dc.identifier.issn1303-6165
dc.identifier.issue4en_US
dc.identifier.pmid36326360en_US
dc.identifier.scopus2-s2.0-85136786393en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage1022en_US
dc.identifier.urihttps://doi.org/10.55730/1300-0144.5404
dc.identifier.urihttps://hdl.handle.net/20.500.12452/16974
dc.identifier.volume52en_US
dc.identifier.wosWOS:000881194200019en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTubitak Scientific & Technological Research Council Turkeyen_US
dc.relation.ispartofTurkish Journal Of Medical Sciencesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectFlot Chemotherapyen_US
dc.subjectPerioperative Treatmenten_US
dc.subjectGastric Canceren_US
dc.subjectGej Tumoren_US
dc.subjectPrognostic Factoren_US
dc.titlePrognostic factors of perioperative FLOT regimen in operable gastric and gastroesophageal junction tumors: real-life data (Turkish Oncology Group)en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu